Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms.
暂无分享,去创建一个
A. Rosenwald | W. Klapper | E. Hoster | M. Engelhard | G. Ott | G. Lenz | E. Leich | K. Herfarth | H. Holte | H. Bernd | K. Beiske | M. Dreyling | F. Micci | O. Weigert | V. Jurinovic | H. Horn | A. Staiger | S. Hartmann | V. Passerini | M. Grau | Myroslav Zapukhlyak | K. Kurz | M. Hansmann | Sabrina Kalmbach | P. Möller | A. Feller | H. Stein | Erik Gaitzsch
[1] A. Rosenwald,et al. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV , 2022, Blood advances.
[2] A. Rosenwald,et al. Follicular lymphoma subgroups with and without t(14;18) differ in their N-glycosylation pattern and IGHV usage , 2021, Blood advances.
[3] A. Rosenwald,et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma , 2021, Nature Communications.
[4] K. Nakayama,et al. Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4. , 2020, Cell reports.
[5] M. Ghielmini,et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] C. Copie-Bergman,et al. Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. , 2020, Blood advances.
[7] Matthew A. Wyczalkowski,et al. Discovery of driver non-coding splice-site-creating mutations in cancer , 2020, Nature Communications.
[8] V. Seshan,et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups , 2020, Blood Cancer Journal.
[9] A. Rosenwald,et al. Localized and Advanced Stage Follicular Lymphomas Differ in their Gene Expression Profiles. , 2019, Blood.
[10] R. Gascoyne,et al. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab , 2019, Journal of Immunotherapy for Cancer.
[11] J. Cerhan,et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.
[12] Y. Wu,et al. Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma , 2016, Blood Cancer Journal.
[13] R. Gascoyne,et al. Cell of origin of transformed follicular lymphoma. , 2015, Blood.
[14] R. Siebert,et al. Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma , 2014, Leukemia.
[15] Michael Unterhalt,et al. The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease. , 2012, Human pathology.
[16] Ash A. Alizadeh,et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. , 2012, Blood.
[17] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[18] P. Deloukas,et al. Signatures of mutation and selection in the cancer genome , 2010, Nature.
[19] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[20] Carolyn J. Brown,et al. Prognostic significance of secondary cytogenetic alterations in follicular lymphomas , 2008, Genes, chromosomes & cancer.
[21] R. Spang,et al. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma , 2008, Haematologica.
[22] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[23] L. Staudt,et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. , 2007, Blood.
[24] P. Leibson,et al. Differential Regulation of Human NK Cell-Mediated Cytotoxicity by the Tyrosine Kinase Itk1 , 2007, The Journal of Immunology.
[25] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[26] J. Zack,et al. CD4 Expression on Activated NK Cells: Ligation of CD4 Induces Cytokine Expression and Cell Migration1 , 2006, The Journal of Immunology.
[27] R. Gascoyne,et al. Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes , 2003, British journal of haematology.
[28] Gouri Nanjangud,et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.
[29] A. Rosenwald,et al. Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus , 2016, Leukemia.
[30] Christian Steidl,et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. , 2009, Blood.
[31] Peter Parham,et al. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. , 2002, Annual review of immunology.